Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 391231140
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,799.40 | 29.30 | -0.33% |
| CAC 40 | 7,766.71 | 43.24 | 0.56% |
| DAX 40 | 24,206.91 | 133.24 | 0.55% |
| Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
| FTSE 100 | 8,854.18 | 47.65 | 0.54% |
| HKSE | 24,148.07 | 260.24 | 1.09% |
| NASDAQ | 20,418.46 | 5.95 | 0.03% |
| Nikkei 225 | 39,633.83 | 54.98 | -0.14% |
| NZX 50 Index | 12,732.84 | 126.18 | -0.98% |
| S&P 500 | 6,225.52 | 4.46 | -0.07% |
| S&P/ASX 200 | 8,562.60 | 28.10 | -0.33% |
| SSE Composite Index | 3,496.97 | 0.51 | -0.01% |